Identification

Name
Morphine
Accession Number
DB00295  (APRD00215, DB05354)
Type
Small Molecule
Groups
Approved, Investigational
Description

The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. In January, 2017, morphine was approved for the treatment of chronic pain.

Structure
Thumb
Synonyms
  • (−)-morphine
  • (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
  • (5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
  • (5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
  • (5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
  • (5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
  • (7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
  • morfina
  • Morphia
  • Morphin
  • Morphinum
  • Morphium
External IDs
IDS-NM-009 / N02AA01
Product Ingredients
IngredientUNIICASInChI Key
Morphine acetateVEO43W5229596-15-6CLDOGJORCNORLA-VYKNHSEDSA-N
Morphine hydrochlorideJ28GE0ROVX52-26-6XCKKIKBIPZJUET-VYKNHSEDSA-N
Morphine mesylateQXB8THK8QY335328-17-1MHEMFNFIWLUDDJ-VYKNHSEDSA-N
Morphine nitrateDV2P23JCWV596-16-7VHBDDUMTLJSZDR-VYKNHSEDSA-N
Morphine phosphate1LQ9207LZE596-17-8KZSZGTYWWBPNKB-VYKNHSEDSA-N
Morphine sulfateDY70C97N3064-31-3USAHOPJHPJHUNS-IFCNUISUSA-N
Morphine sulfate pentahydrateX3P646A2J06211-15-0GRVOTVYEFDAHCL-RTSZDRIGSA-N
Morphine tartrateU3NSU23LHD302-31-8SVTKSKRNLMAUKF-HAIKCVHQSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arymo ERTablet, film coated, extended release30 mg/1OralEgalet Ltd2017-02-01Not applicableUs
Arymo ERTablet, film coated, extended release15 mg/1OralEgalet Ltd2017-02-01Not applicableUs
Arymo ERTablet, film coated, extended release60 mg/1OralEgalet Ltd2017-02-01Not applicableUs
AvinzaCapsule, extended release60 mg/1Oralbryant ranch prepack2002-03-20Not applicableUs
AvinzaCapsule, coated, extended release60 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-10-25Not applicableUs
AvinzaCapsule, extended release60 mg/1OralStat Rx USA2002-03-20Not applicableUs
AvinzaCapsule, extended release60 mg/1OralPfizer Laboratories Div Pfizer Inc.2002-03-202017-01-31Us
AvinzaCapsule, extended release30 mg/1Oralbryant ranch prepack2002-03-20Not applicableUs
AvinzaCapsule, extended release45 mg/1OralPfizer Laboratories Div Pfizer Inc.2002-03-202015-11-30Us
AvinzaCapsule, extended release30 mg/1OralPfizer Laboratories Div Pfizer Inc.2002-03-202015-12-29Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Morphine SulfateCapsule, extended release30 mg/1OralWatson Pharmaceuticals2011-11-10Not applicableUs
Morphine sulfateTablet, film coated, extended release60 mg/1OralRanbaxy Inc.2012-05-11Not applicableUs
Morphine sulfateTablet, film coated, extended release60 mg/1OralActavis Pharma Company2015-10-26Not applicableUs
Morphine SulfateInjection, solution.5 mg/mLEpidural; Intrathecal; IntravenousHospira, Inc.1988-05-112016-10-13Us
Morphine SulfateCapsule, extended release10 mg/1OralUpsher Smith Laboratories, Llc2013-06-30Not applicableUs
Morphine SulfateTablet, extended release100 mg/1OralMallinckrodt2010-10-21Not applicableUs
Morphine SulfateCapsule, extended release30 mg/1OralPar Pharmaceutical2011-11-10Not applicableUs
Morphine SulfateCapsule, extended release80 mg/1OralImpax Generics2016-04-12Not applicableUs
Morphine SulfateTablet, extended release200 mg/1OralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine SulfateTablet, film coated, extended release100 mg/1OralWatson Pharmaceuticals1987-05-01Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Morphine SulfateInjection, solution.5 mg/mLIntrathecal; IntravenousCantrell Drug Company2012-01-23Not applicableUs
Morphine SulfateSuppository5 mg/1RectalPaddock Laboratories, Inc.1990-09-01Not applicableUs
Morphine SulfateInjection5 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical1971-01-012017-07-07Us
Morphine SulfateInjection, solution25 mg/mLIntravenousHospira, Inc.1991-04-112017-02-22Us
Morphine SulfateInjection10 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical1971-01-012017-07-07Us
Morphine SulfateInjection15 mg/mLIntramuscular; Intravenous; SubcutaneousBaxter Laboratories2010-05-262015-12-29Us
Morphine SulfateInjection, solution30 mg/30mLIntravenous; SubcutaneousAmphastar Pharmaceuticals, Inc.1987-03-272016-12-06Us
Morphine SulfateInjection5 mg/mLIntramuscular; Intravenous; SubcutaneousBaxter Laboratories2010-05-262015-12-29Us
Morphine SulfateSuppository20 mg/1RectalPaddock Laboratories, Inc.1990-09-01Not applicableUs
Morphine SulfateInjection15 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical1971-01-012017-07-07Us
International/Other Brands
Kapanol / MSIR / Oramorph / Roxanol
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
EmbedaMorphine (20 mg/1) + Naltrexone hydrochloride (.8 mg/1)Capsule, extended releaseOralPfizer Laboratories Div Pfizer Inc.2009-08-13Not applicableUs
EmbedaMorphine (100 mg/1) + Naltrexone hydrochloride (4 mg/1)Capsule, extended releaseOralPfizer Laboratories Div Pfizer Inc.2009-08-13Not applicableUs
EmbedaMorphine (50 mg/1) + Naltrexone hydrochloride (2 mg/1)Capsule, extended releaseOralPfizer Laboratories Div Pfizer Inc.2009-08-13Not applicableUs
EmbedaMorphine (80 mg/1) + Naltrexone hydrochloride (3.2 mg/1)Capsule, extended releaseOralPfizer Laboratories Div Pfizer Inc.2009-08-13Not applicableUs
EmbedaMorphine (30 mg/1) + Naltrexone hydrochloride (1.2 mg/1)Capsule, extended releaseOralPfizer Laboratories Div Pfizer Inc.2009-08-13Not applicableUs
EmbedaMorphine sulfate pentahydrate (20 mg/1) + Naltrexone hydrochloride (.8 mg/1)Capsule, extended releaseOralStat Rx USA2009-08-13Not applicableUs
EmbedaMorphine (60 mg/1) + Naltrexone hydrochloride (2.4 mg/1)Capsule, extended releaseOralPfizer Laboratories Div Pfizer Inc.2009-08-13Not applicableUs
Categories
UNII
76I7G6D29C
CAS number
57-27-2
Weight
Average: 285.3377
Monoisotopic: 285.136493479
Chemical Formula
C17H19NO3
InChI Key
BQJCRHHNABKAKU-KBQPJGBKSA-N
InChI
InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraene-10,14-diol
SMILES
[H][[email protected]@]12OC3=C(O)C=CC4=C3[[email protected]@]11CCN(C)[[email protected]]([H])(C4)[[email protected]]1([H])C=C[[email protected]@H]2O

Pharmacology

Indication

For the relief and treatment of severe pain.

Structured Indications
Pharmacodynamics

Morphine is a narcotic pain management agent indicated for the relief of pain in patients who require opioid analgesics for more than a few days. Morphine interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, morphine exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Morphine appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers.

Mechanism of action

The precise mechanism of the analgesic action of morphine is unknown. However, specific CNS opiate receptors have been identified and likely play a role in the expression of analgesic effects. Morphine first acts on the mu-opioid receptors. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation. It has been shown that morphine binds to and inhibits GABA inhibitory interneurons. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
AKappa-type opioid receptor
agonist
Human
ADelta-type opioid receptor
agonist
Human
ULymphocyte antigen 96Not AvailableHuman
Absorption

Bioavailability is approximately 30%.

Volume of distribution
  • 1 to 6 L/kg
Protein binding

30-40%

Metabolism

Primarily hepatic (90%), converted to dihydromorphinone and normorphine. Also converted to morphine-3-glucuronide (M3G) and morphine-6-glucuronide. Virtually all morphine is converted to glucuronide metabolites; only a small fraction (less than 5%) of absorbed morphine is demethylated.

Route of elimination

A small amount of glucuronide conjugates are excreted in bile, with minor enterohepatic recycling. Seven to 10% of administered morphine sulfate is excreted in the feces.

Half life

2-4 hours

Clearance
  • 20 – 30 mL/min/kg [Adult]
  • 1852 +/- 116 mL/min [Chinese]
  • 1495 +/- 80 mL/min [Caucasian]
Toxicity

LD50 = 461 mg/kg (rat, oral), 600 mg/kg (mouse, oral). Human lethal dose by ingestion is 120-250 mg of morphine sulfate. Symptoms of overdose include cold, clammy skin, flaccid muscles, fluid in the lungs, lowered blood pressure, "pinpoint" or dilated pupils, sleepiness leading to stupor and coma, slowed breathing, and slow pulse rate.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Codeine Action PathwayDrug action
Heroin Action PathwayDrug action
Heroin Metabolism PathwayDrug metabolism
Morphine Action PathwayDrug action
Codeine Metabolism PathwayDrug metabolism
Morphine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Multidrug resistance protein 1---(T;T) / (C;T)T AlleleEffect Directly StudiedPatients with this genotype may have an increased analgesic response to morphine.Details
Mu-type opioid receptor---(A;A)A AlleleEffect Directly StudiedPatients with this genotype may have an increased analgesic response to morphine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Morphine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Morphine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Morphine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Morphine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Morphine.Experimental
AbirateroneThe serum concentration of Morphine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Morphine is combined with Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Morphine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Morphine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Morphine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Morphine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Morphine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Morphine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Morphine is combined with Agomelatine.Approved, Investigational
AlaproclateMorphine may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Morphine.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Morphine is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Morphine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Morphine.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Morphine is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Morphine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Morphine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Morphine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Alprazolam.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Morphine is combined with Alvimopan.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Morphine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Morphine is combined with Amiloride.Approved
AmiodaroneThe metabolism of Morphine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Morphine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Morphine is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Morphine is combined with Amlodipine.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Morphine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Morphine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Morphine is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Morphine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Morphine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Morphine is combined with Amyl Nitrite.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Morphine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Morphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Morphine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Morphine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Morphine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Morphine.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Morphine.Approved, Investigational
ArtemetherThe metabolism of Morphine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Morphine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Morphine is combined with Asenapine.Approved
AtazanavirThe metabolism of Morphine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Morphine is combined with Atenolol.Approved
AtomoxetineThe metabolism of Morphine can be decreased when combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Morphine.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Morphine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Morphine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Morphine is combined with Azaperone.Investigational, Vet Approved
AzelastineMorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Morphine is combined with Azilsartan medoxomil.Approved
AzosemideThe risk or severity of adverse effects can be increased when Morphine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Morphine is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Morphine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Morphine.Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Morphine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Morphine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Morphine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Morphine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Morphine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Morphine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Morphine is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Morphine.Approved, Withdrawn
BetaxololThe metabolism of Morphine can be decreased when combined with Betaxolol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Morphine.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Morphine is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Morphine.Investigational
BoceprevirThe metabolism of Morphine can be decreased when combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Morphine.Experimental
BortezomibThe metabolism of Morphine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Morphine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Morphine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Morphine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Morphine is combined with Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Morphine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Morphine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Morphine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Morphine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Morphine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Morphine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Morphine is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Morphine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Bupivacaine.Approved, Investigational
BuprenorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Morphine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Morphine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Morphine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Morphine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Morphine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Morphine is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Morphine.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Morphine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Morphine is combined with Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Morphine is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Morphine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Morphine is combined with Canrenone.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Morphine is combined with Captopril.Approved
CarbamazepineThe metabolism of Morphine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Morphine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Morphine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Morphine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Morphine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Morphine is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Morphine is combined with Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Morphine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Morphine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Morphine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Morphine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Morphine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Morphine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Morphine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Morphine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Morphine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Morphine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Morphine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Morphine is combined with Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Morphine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Morphine.Approved, Investigational
CimetidineThe metabolism of Morphine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Morphine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Morphine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Morphine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Morphine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Morphine is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Morphine is combined with Clidinium.Approved
ClobazamThe metabolism of Morphine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Morphine.Approved, Investigational
ClofenamideThe risk or severity of adverse effects can be increased when Morphine is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Morphine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Morphine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Morphine is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Morphine is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Morphine is combined with Clopenthixol.Experimental
ClopidogrelMorphine may decrease the antiplatelet activities of Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Morphine is combined with Clorazepate.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Morphine is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Morphine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Morphine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Morphine.Approved
CobicistatThe serum concentration of Morphine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Morphine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Morphine is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Morphine.Approved
ConivaptanThe serum concentration of Morphine can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Morphine can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Morphine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Morphine.Approved
CyclosporineThe metabolism of Morphine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Morphine.Approved
DabrafenibThe serum concentration of Morphine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Morphine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Morphine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Morphine is combined with Dapiprazole.Approved
DapoxetineMorphine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Morphine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Morphine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Morphine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Morphine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Morphine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Morphine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Desflurane.Approved
DesipramineThe metabolism of Morphine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Morphine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.Approved
DesvenlafaxineMorphine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Morphine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Morphine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Morphine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Morphine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Morphine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Morphine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Morphine is combined with Diclofenamide.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Morphine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Morphine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Morphine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Morphine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Morphine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Morphine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Morphine is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Morphine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Morphine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Morphine is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Morphine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Morphine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Morphine can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Morphine is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Morphine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Morphine.Approved, Investigational
DoxycyclineThe metabolism of Morphine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Morphine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Illicit
DronedaroneThe metabolism of Morphine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Morphine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Morphine is combined with Drotebanol.Experimental, Illicit
DuloxetineMorphine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Morphine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Morphine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Morphine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Morphine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Morphine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Morphine is combined with Efonidipine.Approved, Investigational
EliglustatThe metabolism of Morphine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Morphine is combined with Eltanolone.Investigational
EluxadolineMorphine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Morphine.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Morphine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Morphine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Morphine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Morphine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Morphine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Morphine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Morphine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Morphine is combined with Eprosartan.Approved
ErythromycinThe metabolism of Morphine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramMorphine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Morphine is combined with Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Morphine is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Morphine is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Morphine.Experimental
EthanolMorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Morphine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Morphine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Morphine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Morphine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Morphine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Morphine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Morphine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Morphine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Morphine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Morphine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Morphine is combined with Etomidate.Approved
EtoperidoneMorphine may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Morphine.Experimental
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Morphine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Morphine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Morphine is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Morphine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Morphine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Morphine.Approved
FenquizoneThe risk or severity of adverse effects can be increased when Morphine is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Morphine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Morphine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Morphine is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Morphine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Morphine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Morphine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Morphine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Morphine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Morphine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Morphine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Morphine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Morphine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Morphine is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Morphine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Morphine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Morphine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Morphine is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Morphine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Morphine is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Morphine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Morphine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Morphine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Morphine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Morphine is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Morphine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Morphine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Morphine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of Morphine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Morphine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Morphine is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Morphine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Morphine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Morphine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Morphine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Morphine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Morphine is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Morphine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Morphine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Morphine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Morphine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneMorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Morphine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Morphine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Morphine.Approved
IbopamineThe risk or severity of adverse effects can be increased when Morphine is combined with Ibopamine.Experimental
IloperidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Morphine.Approved, Investigational
ImatinibThe metabolism of Morphine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Morphine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Morphine.Approved
IndalpineMorphine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Morphine is combined with Indapamide.Approved
IndinavirThe metabolism of Morphine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Morphine is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Morphine.Withdrawn
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Morphine.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Morphine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Morphine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Morphine.Withdrawn
IrbesartanThe metabolism of Morphine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Morphine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Morphine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Morphine can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Morphine is combined with Isosorbide.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Morphine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Morphine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Morphine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Morphine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Morphine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Morphine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Morphine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Morphine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Morphine is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Morphine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Morphine is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Morphine can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Morphine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Morphine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Morphine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Morphine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Morphine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Morphine is combined with Levocetirizine.Approved
LevodopaMorphine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Morphine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranMorphine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Morphine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Morphine.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Morphine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Morphine is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Morphine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Morphine.Approved, Investigational
LopinavirThe metabolism of Morphine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Morphine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Morphine.Approved
LorcaserinThe metabolism of Morphine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Lormetazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Morphine is combined with Losartan.Approved
LovastatinThe metabolism of Morphine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Morphine is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Morphine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Morphine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Morphine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Vet Approved
ManidipineThe metabolism of Morphine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Morphine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Morphine is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Morphine.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Morphine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Morphine is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Morphine is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Morphine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Morphine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Morphine is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Morphine is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Morphine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Morphine is combined with Melperone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of Morphine.Investigational
MephentermineMephentermine may increase the analgesic activities of Morphine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Morphine is combined with Meprobamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Morphine is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Morphine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Morphine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Morphine is combined with Metaxalone.Approved
MethadoneThe metabolism of Morphine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Morphine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Morphine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Morphine.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Morphine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Morphine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Morphine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Morphine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Morphine is combined with Methohexital.Approved
MethotrimeprazineMorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Morphine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Morphine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Morphine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Morphine is combined with Methylecgonine.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Morphine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Morphine.Approved
MeticraneThe risk or severity of adverse effects can be increased when Morphine is combined with Meticrane.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Morphine is combined with Metipranolol.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Morphine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Morphine is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Morphine is combined with Metoprolol.Approved, Investigational
MetyrosineMorphine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Midazolam.Approved, Illicit
MidomafetamineMidomafetamine may increase the analgesic activities of Morphine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Morphine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Morphine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMorphine may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Morphine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Morphine is combined with Minoxidil.Approved
MirabegronThe metabolism of Morphine can be decreased when combined with Mirabegron.Approved
MirtazapineMorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Morphine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Morphine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Morphine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Morphine is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Morphine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Morphine.Approved, Investigational, Withdrawn
MoxonidineThe risk or severity of adverse effects can be increased when Morphine is combined with Moxonidine.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Morphine is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Morphine is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Morphine.Approved
NaltrexoneThe therapeutic efficacy of Morphine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Morphine is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Morphine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Morphine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Morphine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Morphine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Morphine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Morphine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Morphine is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Morphine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Morphine is combined with Nifedipine.Approved
NilotinibThe metabolism of Morphine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Morphine is combined with Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Morphine is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Morphine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Morphine is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Morphine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Morphine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Morphine is combined with Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Morphine is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Morphine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Morphine is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Morphine is combined with Obinutuzumab.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Morphine.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Morphine is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Morphine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Morphine is combined with Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Morphine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Morphine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Morphine is combined with Opium.Approved, Illicit
OrphenadrineMorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Morphine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Morphine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Morphine.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxethazaine.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Morphine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Morphine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Morphine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Morphine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Morphine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Morphine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Morphine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Morphine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Paliperidone.Approved
PamabromThe risk or severity of adverse effects can be increased when Morphine is combined with Pamabrom.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Morphine.Approved
PanobinostatThe serum concentration of Morphine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Morphine is combined with Papaverine.Approved
ParaldehydeMorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Morphine.Approved
ParoxetineThe metabolism of Morphine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Morphine.Approved
Peginterferon alfa-2bThe serum concentration of Morphine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Morphine is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Morphine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Morphine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Morphine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Morphine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved
PerazineThe risk or severity of adverse effects can be increased when Morphine is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Morphine is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Morphine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Morphine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Morphine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Morphine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Morphine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Morphine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Morphine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Morphine.Withdrawn
PhenobarbitalThe metabolism of Morphine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Morphine is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Morphine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Morphine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Morphine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Morphine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Morphine is combined with Phentolamine.Approved
PhenytoinThe metabolism of Morphine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Morphine is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Morphine is combined with Pindolol.Approved
PioglitazoneThe metabolism of Morphine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Morphine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Morphine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Morphine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Morphine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Morphine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Morphine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Morphine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Morphine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Morphine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Morphine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Morphine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleMorphine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Morphine is combined with Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Morphine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Morphine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Morphine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Morphine is combined with Prochlorperazine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Morphine.Approved
PromazineThe metabolism of Morphine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Morphine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Morphine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Morphine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Proparacaine.Approved, Vet Approved
PropericiazinePropericiazine may increase the hypotensive activities of Morphine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Morphine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Morphine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Morphine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Morphine is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Morphine is combined with Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Morphine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Morphine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Morphine.Approved
PSD502The risk or severity of adverse effects can be increased when Morphine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Morphine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Morphine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Morphine is combined with Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Morphine is combined with Quinethazone.Approved
QuinidineThe metabolism of Morphine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Morphine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Quinisocaine.Experimental
RabeprazoleThe metabolism of Morphine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Morphine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Morphine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Morphine is combined with Ramipril.Approved
RamosetronMorphine may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Morphine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Morphine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Morphine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Morphine is combined with Reserpine.Approved, Investigational
RifabutinThe serum concentration of Morphine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Morphine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Morphine can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Morphine.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Morphine is combined with Riociguat.Approved
RisperidoneMorphine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Morphine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Morphine.Investigational
RitonavirThe metabolism of Morphine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Morphine can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Morphine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Morphine is combined with Romifidine.Vet Approved
RopiniroleMorphine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Ropivacaine.Approved
RosiglitazoneThe metabolism of Morphine can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineMorphine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Morphine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Morphine is combined with Sacubitril.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Morphine.Withdrawn
SaquinavirThe metabolism of Morphine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Morphine is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Morphine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Morphine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Morphine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Morphine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Morphine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Morphine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Morphine.Approved
SiltuximabThe serum concentration of Morphine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Morphine can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Morphine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Morphine.Approved
SotalolThe risk or severity of adverse effects can be increased when Morphine is combined with Sotalol.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Morphine is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Morphine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Morphine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Morphine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Morphine is combined with Streptokinase.Approved, Investigational
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Morphine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil.Approved, Investigational
SulfamethoxazoleThe metabolism of Morphine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Morphine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Morphine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Morphine is combined with Sultopride.Experimental
SuvorexantMorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe metabolism of Morphine can be decreased when combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Morphine is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Morphine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Morphine is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Morphine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Morphine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Morphine is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Morphine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Morphine is combined with Terazosin.Approved
TerbinafineThe metabolism of Morphine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe metabolism of Morphine can be decreased when combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrodotoxin.Investigational
ThalidomideMorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Morphine is combined with Theobromine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Morphine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Morphine.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Morphine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Morphine is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Morphine.Approved
ThioridazineThe metabolism of Morphine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Morphine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Morphine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Morphine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Morphine can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Morphine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Morphine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Morphine is combined with Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Morphine is combined with Timolol.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Morphine.Approved
TipranavirThe metabolism of Morphine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Morphine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Morphine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Morphine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Morphine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Morphine.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Morphine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Morphine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Morphine is combined with Topiramate.Approved
TopiroxostatThe metabolism of Morphine can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Morphine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Morphine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Morphine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Morphine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Morphine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Morphine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Morphine is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Morphine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Morphine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Morphine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Morphine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Morphine is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Morphine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Morphine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Morphine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Morphine.Approved, Investigational
TrimethoprimThe metabolism of Morphine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Morphine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Morphine is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Morphine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Morphine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Morphine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Morphine.Approved
UlaritideThe risk or severity of adverse effects can be increased when Morphine is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Morphine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Morphine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Morphine is combined with Valsartan.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Morphine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Morphine.Approved
VenlafaxineThe metabolism of Morphine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Morphine is combined with Veralipride.Experimental
VerapamilThe metabolism of Morphine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Morphine is combined with Vigabatrin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Morphine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Morphine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Morphine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Morphine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Morphine is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Morphine is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Morphine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Morphine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Morphine is combined with Ziconotide.Approved
ZimelidineMorphine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Morphine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Zolazepam.Vet Approved
ZolpidemMorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Morphine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Morphine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Morphine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Morphine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).

References

Synthesis Reference

Nagaraj R. Ayyangar, Anil R. Choudhary, Uttam R. Kalkote, Vasant K. Sharma, "Process for the preparation of codeine from morphine." U.S. Patent US4764615, issued May, 1912.

US4764615
General References
  1. Kilpatrick GJ, Smith TW: Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005 Sep;25(5):521-44. [PubMed:15952175]
  2. Loguinov AV, Anderson LM, Crosby GJ, Yukhananov RY: Gene expression following acute morphine administration. Physiol Genomics. 2001 Aug 28;6(3):169-81. [PubMed:11526201]
External Links
Human Metabolome Database
HMDB14440
KEGG Drug
D08233
KEGG Compound
C01516
PubChem Compound
5288826
PubChem Substance
46505161
ChemSpider
4450907
BindingDB
50000092
ChEBI
17303
ChEMBL
CHEMBL70
Therapeutic Targets Database
DAP000071
PharmGKB
PA450550
HET
MOI
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Morphine
ATC Codes
N02AA51 — Morphine, combinationsN02AA01 — MorphineA07DA52 — Morphine, combinationsN02AG01 — Morphine and antispasmodics
AHFS Codes
  • 28:08.08 — Opiate Agonists
PDB Entries
1q0y
FDA label
Download (1.2 MB)
MSDS
Download (51.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedSupportive CareCancer, Ovarian / Cervical Cancers / Uterine Endometrial Cancer1
0CompletedTreatmentRenal Colic1
0Not Yet RecruitingDiagnosticVasoplegia1
0RecruitingTreatmentPain1
1Active Not RecruitingTreatmentPain1
1CompletedNot AvailableGastric Emptying / Healthy Volunteers1
1CompletedNot AvailableHealthy Volunteers3
1CompletedNot AvailablePain1
1CompletedBasic ScienceDrug Induced Constipation1
1CompletedBasic ScienceHealthy Volunteers5
1CompletedBasic ScienceNondependent Opioid Abuse, Episodic1
1CompletedDiagnosticFatty Liver1
1CompletedTreatmentCancers / Pain1
1CompletedTreatmentDrug withdrawal syndrome neonatal2
1CompletedTreatmentPain, Acute1
1CompletedTreatmentRestless Legs Syndrome (RLS)1
1RecruitingTreatmentHeroin Dependence / Opioid Use Disorders1
1RecruitingTreatmentLow Back Pain (LBP)1
1RecruitingTreatmentRenal Colic1
1TerminatedSupportive CareCancers1
1Unknown StatusNot AvailableHealthy Volunteers1
1Unknown StatusTreatmentObstructive Sleep Apnea of Adult1
1, 2Active Not RecruitingTreatmentOpioid Abuse / Opioid Dependence1
1, 2CompletedBasic ScienceHealthy Volunteers1
1, 2CompletedTreatmentPain1
1, 2CompletedTreatmentPain, Acute1
1, 2CompletedTreatmentPostoperative pain1
1, 2Not Yet RecruitingBasic ScienceDrug Effect / Pain1
1, 2RecruitingTreatmentImmune System Suppression1
1, 2RecruitingTreatmentPain, Acute1
1, 2RecruitingTreatmentPain, Acute / Pain, Chronic1
1, 2Unknown StatusNot AvailableClose Head Injury / Head Trauma / Subarachnoid Hemorrhage1
2Active Not RecruitingTreatmentAdenotonsillitis / Tonsillitis1
2Active Not RecruitingTreatmentPain1
2Active Not RecruitingTreatmentPostoperative pain1
2CompletedOtherAllelic Frequencies of Genetic Markers / Pain / Polymorphism-Genetic1
2CompletedPreventionCoagulation Defect; Bleeding1
2CompletedPreventionRotator Cuff Syndrome1
2CompletedSupportive CareCancers / Pain1
2CompletedSupportive CareMucositis1
2CompletedSupportive CarePain1
2CompletedSupportive CarePain / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentAmputations / Pain, Chronic1
2CompletedTreatmentHallux Valgus1
2CompletedTreatmentHeroin Dependence / Opioid-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentHysterectomy1
2CompletedTreatmentOpioid-Related Disorders2
2CompletedTreatmentPain4
2CompletedTreatmentPain, Acute2
2CompletedTreatmentPain, Acute / Pain, Chronic1
2CompletedTreatmentPost Operative Pain1
2CompletedTreatmentPost-Operative Pain1
2CompletedTreatmentPost-Operative Pain / Third Molar Extraction1
2CompletedTreatmentPostoperative pain2
2CompletedTreatmentPregnant Women1
2CompletedTreatmentPremature Neonates1
2CompletedTreatmentProgressive Infantile Idiopathic Scoliosis1
2CompletedTreatmentRadicular syndrome / Sciatica1
2CompletedTreatmentRenal Colic1
2Enrolling by InvitationTreatmentDrug withdrawal syndrome neonatal / Neonatal Withdrawal Syndrome1
2Not Yet RecruitingSupportive CareAnaesthesia therapy / Block / General Surgery / Thoracic Injury1
2Not Yet RecruitingSupportive CarePain Management1
2Not Yet RecruitingTreatmentPain Management1
2Not Yet RecruitingTreatmentPain, Acute1
2Not Yet RecruitingTreatmentPain, Chronic1
2RecruitingPreventionPostoperative pain1
2RecruitingTreatmentCesarean Section / Pain1
2RecruitingTreatmentPain1
2RecruitingTreatmentPain, Neuropathic1
2RecruitingTreatmentPost-Operative Pain1
2RecruitingTreatmentPostoperative Cognitive Dysfunction1
2RecruitingTreatmentPostoperative pain1
2RecruitingTreatmentRespiratory Depression1
2TerminatedTreatmentAnalgesia1
2TerminatedTreatmentNeoplasms / Pain1
2TerminatedTreatmentPain1
2Unknown StatusSupportive CareMetastatic Cancers1
2Unknown StatusSupportive CareMetastatic Cancers / Pain / Unspecified Adult Solid Tumor, Protocol Specific1
2Unknown StatusTreatmentOpioid-Related Disorders1
2Unknown StatusTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
2WithdrawnTreatmentHb-SS Disease With Vasoocclusive Pain / Hemoglobin SS Disease With Crisis / Hemoglobin SS Disease With Vasoocclusive Crisis / Other Sickle Cell Disease With Vaso-Occlusive Pain / Sickle Cell Disorders1
2WithdrawnTreatmentPain1
2, 3Active Not RecruitingDiagnosticCancer, Breast1
2, 3CompletedNot AvailablePain1
2, 3CompletedPreventionPruritus1
2, 3CompletedSupportive CareChronic Obstructive Pulmonary Disease (COPD)1
2, 3CompletedTreatmentAcute Agitation / Dementias / Pain1
2, 3CompletedTreatmentAnaesthesia therapy1
2, 3CompletedTreatmentBMI >30 kg/m2 / Diabetes Mellitus (DM) / High Blood Pressure (Hypertension) / Sleep Apnea Syndrome1
2, 3CompletedTreatmentClosed Multiple Fractures of Upper and Lower Limbs1
2, 3CompletedTreatmentPostoperative pain1
2, 3CompletedTreatmentSedation therapy1
2, 3CompletedTreatmentVesicular Stomatitis1
2, 3RecruitingTreatmentKnee Arthritis1
2, 3RecruitingTreatmentPost Surgical Pain1
2, 3RecruitingTreatmentPostoperative pain1
3Active Not RecruitingTreatmentDrug withdrawal syndrome neonatal / Neonatal Opioid Withdrawal1
3Active Not RecruitingTreatmentOsteoarthritis (OA) / Pain1
3Active Not RecruitingTreatmentPain / Sickle Cell Disorders1
3CompletedSupportive CareCancers, Pain1
3CompletedSupportive CareChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Pain / Precancerous/Nonmalignant Condition / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentAbscesses / Pain1
3CompletedTreatmentBunionectomy / Pain / Pain, Acute / Postoperative pain1
3CompletedTreatmentCancers2
3CompletedTreatmentDrug withdrawal syndrome neonatal2
3CompletedTreatmentHerpes Zoster / Pain1
3CompletedTreatmentHysterectomy / Postoperative1
3CompletedTreatmentModerate to Severe Postoperative Pain1
3CompletedTreatmentNeoplasms1
3CompletedTreatmentNewborn Infants / Pain1
3CompletedTreatmentOsteoarthritis (OA) / Pain, Chronic1
3CompletedTreatmentOther Acute Postoperative Pain1
3CompletedTreatmentPain1
3CompletedTreatmentPain, Acute3
3CompletedTreatmentPain / Skin Transplantation1
3CompletedTreatmentPost Traumatic Pain1
3CompletedTreatmentPostoperative pain9
3CompletedTreatmentPruritus1
3CompletedTreatmentRenal Colic1
3CompletedTreatmentRenal Stones1
3CompletedTreatmentScoliosis1
3CompletedTreatmentSedation therapy1
3Not Yet RecruitingTreatmentOpioid Dependence1
3Not Yet RecruitingTreatmentPain, Acute1
3Not Yet RecruitingTreatmentParecoxib / Rib Fractures1
3RecruitingSupportive CareObstructive Sleep Apnoea (OSA)1
3RecruitingSupportive CarePain, Intractable1
3RecruitingSupportive CarePreoperative Sedation1
3RecruitingTreatmentBMI >30 kg/m21
3RecruitingTreatmentCancer: Breakthrough Pain / Cancer: Extreme Pain on Movement1
3RecruitingTreatmentCancers / Pain1
3RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD) / Dyspnea1
3RecruitingTreatmentColorectal Cancers / Other Complications / Pain1
3RecruitingTreatmentKnee Replacement Surgery / Osteoarthritis (OA) / Pain Management1
3RecruitingTreatmentPain Management1
3RecruitingTreatmentPain / Scoliosis1
3RecruitingTreatmentPostoperative pain2
3TerminatedTreatmentCancer, Advanced / Tumors, Solid1
3TerminatedTreatmentChronic Wounds / Local Pain1
3TerminatedTreatmentPain1
3Unknown StatusSupportive CareSigmoidal Tumour1
3Unknown StatusTreatmentBreakthrough Cancer Pain1
3Unknown StatusTreatmentCancers1
3Unknown StatusTreatmentEmergency / Pain / Traumatic Injuries1
3Unknown StatusTreatmentPediatric Obstructive Sleep Apnea Syndrome1
3Unknown StatusTreatmentWounds1
3WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD) / Dyspnea1
4Active Not RecruitingNot AvailablePain1
4Active Not RecruitingNot AvailablePain, Acute1
4Active Not RecruitingTreatmentArthroplasty, Replacement, Hip1
4CompletedNot AvailableAbdominal Pain (AP)1
4CompletedNot AvailableCardiovascular Disease (CVD)1
4CompletedNot AvailableEnd Stage Liver Diseases / Lung Cancers1
4CompletedBasic SciencePain1
4CompletedBasic SciencePharyngeal Dysfunction / Pharyngeal Swallowing1
4CompletedDiagnosticAppendicitis1
4CompletedDiagnosticChronic Low Back Pain (CLBP) / Opioid-Induced Hyperalgesia1
4CompletedDiagnosticPruritus1
4CompletedDiagnosticSphincter of Oddi Dysfunction1
4CompletedHealth Services ResearchIntestinal Obstruction1
4CompletedPreventionDelirium1
4CompletedPreventionNausea and Vomiting, Postoperative / Postoperative pain1
4CompletedPreventionOveractive Bladder / Painful Bladder Syndrome (PBS) / Urinary Bladder, Neurogenic / Urinary Urge Incontinence1
4CompletedPreventionPain1
4CompletedSupportive CareAppendicitis1
4CompletedSupportive CareHysterectomy (MeSH nr: E04.950.300.399)1
4CompletedSupportive CarePain / Unspecified Adult Solid Tumor, Protocol Specific1
4CompletedSupportive CarePost Operative Pain1
4CompletedSupportive CareSickle Cell Disorders1
4CompletedTreatmentAbdominal Hysterectomy (& Wertheim)1
4CompletedTreatmentAcute Coronary Syndromes (ACS)1
4CompletedTreatmentAcute Pain Management / Renal Colic1
4CompletedTreatmentAcute Postoperative Pain1
4CompletedTreatmentAnalgesia1
4CompletedTreatmentAnalgesia, Obstetrical / Cesarean Section1
4CompletedTreatmentAnalgesia, Postoperative / Pediatric Adenotonsillectomy1
4CompletedTreatmentAnalgesia / Postoperative pain1
4CompletedTreatmentAnalgesics / Pain, Chronic / Postoperative pain1
4CompletedTreatmentArterial Hypotension / Cesarean Section / Pregnancy / Spinal Anaesthesia1
4CompletedTreatmentBariatric Surgery Candidate / Obesity, Morbid1
4CompletedTreatmentBenign muscle neoplasm / Hysterectomy / Opioids / Postoperative pain1
4CompletedTreatmentCRP1
4CompletedTreatmentCaesarian Section1
4CompletedTreatmentCancers / Pain, Cancer1
4CompletedTreatmentCesarean Section / Prophylaxis against postoperative nausea and vomiting / Spinal Anaesthesia1
4CompletedTreatmentChildren / Postoperative pain / Recovery of Function1
4CompletedTreatmentChlorzoxazone / Postoperative pain1
4CompletedTreatmentChronic Low Back Pain (CLBP) / Depression / Feeling Anxious / Intervertebral Disc Degeneration1
4CompletedTreatmentChronic Lung Diseases / Solitary Mass1
4CompletedTreatmentCoronary Artery Disease1
4CompletedTreatmentDisk Prolapse / Intervertebral Disk Displacement1
4CompletedTreatmentDissecting Aneurysm of the Thoracic Aorta1
4CompletedTreatmentDrug Interaction Potentiation / Myocardial Infarction (MI) / VA Drug Interactions [VA Drug Interaction]1
4CompletedTreatmentDrug withdrawal syndrome neonatal1
4CompletedTreatmentFemur Fractures / Postoperative pain1
4CompletedTreatmentGall Stone Disease1
4CompletedTreatmentGeneral Surgery1
4CompletedTreatmentHeart Diseases1
4CompletedTreatmentHeart; Dysfunction Postoperative, Cardiac Surgery1
4CompletedTreatmentHip Fractures1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)2
4CompletedTreatmentKnee Replacement Surgery / Post Operative Pain1
4CompletedTreatmentLow Back Pain (LBP)1
4CompletedTreatmentMalignant Neoplasm of Stomach1
4CompletedTreatmentMucositis / Pain1
4CompletedTreatmentNon ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Segment Elevation Myocardial Infarction (STEMI) / VA Drug Interactions / VA Drug Interactions [VA Drug Interaction]1
4CompletedTreatmentCaudal epidural block therapy / Orthopedic Procedures / Shoulder1
4CompletedTreatmentOsteoarthritis (OA)1
4CompletedTreatmentOsteoarthritis (OA) / Pain, Chronic1
4CompletedTreatmentOsteoarthritis (OA) / Post-Operative Pain1
4CompletedTreatmentOtitis Media (OM)1
4CompletedTreatmentPain11
4CompletedTreatmentPain, Acute3
4CompletedTreatmentPain, Acute / Sickle Cell Crisis1
4CompletedTreatmentPain, Cancer1
4CompletedTreatmentPain, Chronic2
4CompletedTreatmentPost Operative Pain2
4CompletedTreatmentPost-Operative Pain1
4CompletedTreatmentPostoperative Function Level / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentPostoperative pain4
4CompletedTreatmentRenal Colic / Urinary Calculi1
4CompletedTreatmentSedation therapy1
4CompletedTreatmentSevere, Acute Pain in a Pre-hospital Setting1
4CompletedTreatmentUrolithiasis1
4CompletedTreatmentVideo-assisted Thoracoscopic Surgery (VATS)1
4Not Yet RecruitingTreatmentAcute Pulmonary Edema1
4Not Yet RecruitingTreatmentAnalgesia, Patient-Controlled / Anesthesia; Spinal / Intravenous Drug Delivery Systems / Lumbar epidural anesthesia / Morphine / Surgery, Colorectal1
4Not Yet RecruitingTreatmentDrug withdrawal syndrome neonatal1
4Not Yet RecruitingTreatmentLow Back Pain (LBP)1
4Not Yet RecruitingTreatmentPain1
4Not Yet RecruitingTreatmentPostoperative pain2
4Not Yet RecruitingTreatmentRenal Colic1
4Not Yet RecruitingTreatmentSupratentorial Neoplasms1
4RecruitingPreventionAnaesthesia therapy / Hip Fractures1
4RecruitingPreventionHyperalgesia1
4RecruitingPreventionPostdural Puncture Headache1
4RecruitingSupportive CareBreakthrough Pain / Gastrostomy / Neoplasms, Upper Aerodigestive Tract1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingSupportive CareRight Ventricular Dysfunction1
4RecruitingTreatmentAnalgesia, Obstetrical1
4RecruitingTreatmentAnalgesia, Postoperative1
4RecruitingTreatmentArthroplasty / Osteoarthritis (OA)1
4RecruitingTreatmentBreakthrough Pain / Pain, Chronic / Pain, Intractable1
4RecruitingTreatmentCesarean Section / Pain Management / Pain, Neuropathic1
4RecruitingTreatmentDrug Abuse / Narcotic Abuse / Opiate Addiction / Opioid-Related Disorders1
4RecruitingTreatmentDrug withdrawal syndrome neonatal1
4RecruitingTreatmentDyspnea / Interstitial Lung Disease (ILD) / Morphine1
4RecruitingTreatmentFracture, Ankle / Postoperative pain1
4RecruitingTreatmentHallux Valgus1
4RecruitingTreatmentInjections, Spinal / Morphine / Patients Satisfaction / Prostatectomy1
4RecruitingTreatmentMalignant Neoplasm of Colon / Minimal Residual Disease1
4RecruitingTreatmentMastectomy / Pain, Acute / Pain, Chronic / Wound Infusion1
4RecruitingTreatmentNalbuphine , Morphine / Postoperative pain1
4RecruitingTreatmentNumeric Pain Rating Scale > 5 / 10 / Severe Traumatic Pain1
4RecruitingTreatmentPain2
4RecruitingTreatmentPain, Acute1
4RecruitingTreatmentPain, Chronic1
4RecruitingTreatmentPectus Excavatum1
4RecruitingTreatmentPost-Operative Pain1
4RecruitingTreatmentPostoperative pain1
4RecruitingTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
4RecruitingTreatmentSciatica1
4SuspendedTreatmentPain, Chronic1
4TerminatedHealth Services ResearchIntestinal Obstruction2
4TerminatedPreventionPostoperative Pain Management / Scheduled Cesarean Sections / Side Effects1
4TerminatedSupportive CareChronic Diseases / Pain1
4TerminatedTreatmentAcute Pain, Postoperative1
4TerminatedTreatmentAnesthesia Recovery Period / Postoperative pain1
4TerminatedTreatmentFracture of Neck of Femur1
4TerminatedTreatmentOsteoarthritis (OA) / Postoperative pain1
4TerminatedTreatmentPain1
4TerminatedTreatmentPostoperative pain1
4TerminatedTreatmentRib Fractures1
4Unknown StatusDiagnosticLiver Diseases1
4Unknown StatusTreatmentAcute Abdomen / Back Pain, Acute / Extremity Pain, Acute / Flank Pain, Acute / Other Acute Pain1
4Unknown StatusTreatmentDrug withdrawal syndrome neonatal1
4Unknown StatusTreatmentFracture Bone / Postoperative pain1
4Unknown StatusTreatmentFracture of Neck of Femur1
4Unknown StatusTreatmentInflammatory Disorder of Immune System / Sepsis1
4Unknown StatusTreatmentLow Back Pain (LBP)1
4Unknown StatusTreatmentObesity, Morbid1
4Unknown StatusTreatmentPain2
4Unknown StatusTreatmentPain, Acute1
4Unknown StatusTreatmentPain, Chronic1
4Unknown StatusTreatmentPostoperative pain2
4Unknown StatusTreatmentRenal Colic1
4WithdrawnBasic ScienceSickle Cell Disorders1
4WithdrawnPreventionAutogenous Bone Grafts1
4WithdrawnSupportive CareFracture Bone / Lower Limb Injuries1
4WithdrawnTreatmentArthroplasty, Replacement, Knee / Knee Osteoarthritis (Knee OA)1
4WithdrawnTreatmentPain, Acute / Postoperative pain / Surgery, Colorectal1
4WithdrawnTreatmentTotal Knee Arthroplasty (TKA)1
4WithdrawnTreatmentTraumatic Vaginal Delivery1
Not AvailableActive Not RecruitingHealth Services ResearchPostoperative Complications1
Not AvailableActive Not RecruitingSupportive CarePostoperative pain1
Not AvailableActive Not RecruitingTreatmentAbdominal Surgeries / Thoracic Surgery1
Not AvailableActive Not RecruitingTreatmentMajor Abdominal Surgeries1
Not AvailableCompletedNot AvailableBreakthrough Cancer Pain / Pain, Cancer / Pain, Neuropathic / Tumors1
Not AvailableCompletedNot AvailableInfant, Newborn, Diseases / Pain1
Not AvailableCompletedNot AvailablePain1
Not AvailableCompletedBasic SciencePain1
Not AvailableCompletedDiagnosticDyspnea1
Not AvailableCompletedPreventionAnalgesia / Spinal Anaesthesia / Tranurethral Resection of Prostate1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedSupportive CareLower Extremities Fracture1
Not AvailableCompletedSupportive CareOsteoarthritis (OA) / Post-traumatic; Arthrosis1
Not AvailableCompletedSupportive CarePostoperative Pain Treatment for Total Knee Arthroplasty1
Not AvailableCompletedSupportive CareRespiratory Failure1
Not AvailableCompletedTreatmentAcute Renal Colic1
Not AvailableCompletedTreatmentAnalgesia1
Not AvailableCompletedTreatmentAnalgesia Post Fracture / Upper Extremity Fractures1
Not AvailableCompletedTreatmentAnalgesia, Postoperative1
Not AvailableCompletedTreatmentArthroplasty, Replacement, Hip1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Pain1
Not AvailableCompletedTreatmentCancer, Breast / Postoperative pain1
Not AvailableCompletedTreatmentCancers / Mucositis1
Not AvailableCompletedTreatmentCesarean Delivery1
Not AvailableCompletedTreatmentCritical Illness1
Not AvailableCompletedTreatmentHemodynamics After Spinal Anesthesia1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis, Hip / Osteoarthritis, Shoulder1
Not AvailableCompletedTreatmentLiving Donor Hepatectomy1
Not AvailableCompletedTreatmentMusculoskeletal Injuries1
Not AvailableCompletedTreatmentPain4
Not AvailableCompletedTreatmentPost Cesarean Pain Management1
Not AvailableCompletedTreatmentPost Operative Pain1
Not AvailableCompletedTreatmentPost Operative Pain Management1
Not AvailableCompletedTreatmentPost-Op Complication1
Not AvailableCompletedTreatmentPostoperative pain5
Not AvailableCompletedTreatmentReconstruction Breast Surgery1
Not AvailableCompletedTreatmentRenal Stones1
Not AvailableCompletedTreatmentUltrasound Therapy; Complications1
Not AvailableNot Yet RecruitingTreatmentAcute Myocardial Infarction (AMI)1
Not AvailableNot Yet RecruitingTreatmentChildren / Feeling Anxious / Minor burns / Pain1
Not AvailableNot Yet RecruitingTreatmentInguinal Surgery1
Not AvailableNot Yet RecruitingTreatmentInterscalene Block / Regional Anesthesia / Shoulder Surgery1
Not AvailableNot Yet RecruitingTreatmentPostoperative pain1
Not AvailableNot Yet RecruitingTreatmentPrimary Osteoarthritis of Knee Nos1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableAnesthesia and Analgesia / Cardiac Output / Pneumonectomy; Status / Robotic Surgical Procedures1
Not AvailableRecruitingNot AvailableHealthy Controls1
Not AvailableRecruitingBasic SciencePain / Sleep Deprivation1
Not AvailableRecruitingOtherPain Management in Pregnant Women1
Not AvailableRecruitingPreventionPostoperative pain1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingScreeningPerfusions1
Not AvailableRecruitingSupportive CareInguinal Hernias / Postoperative pain1
Not AvailableRecruitingSupportive CarePostoperative pain1
Not AvailableRecruitingSupportive CarePostoperative pain / Undescended Testis1
Not AvailableRecruitingTreatmentAnaesthesia therapy / Anesthesia Morbidity / Breast Neoplasm Female / Regional Anesthesia / Regional Anesthesia Morbidity1
Not AvailableRecruitingTreatmentAnalgesia, Obstetrical / Obstetric Surgical Procedures1
Not AvailableRecruitingTreatmentCancers1
Not AvailableRecruitingTreatmentCerebrospinal Fluid Leaks / Post-Lumbar Puncture Headache / Postdural Puncture Headache1
Not AvailableRecruitingTreatmentFracture Bone / Pain, Acute1
Not AvailableRecruitingTreatmentHip Fractures1
Not AvailableRecruitingTreatmentNeoplasms, Pancreatic1
Not AvailableRecruitingTreatmentObstructive Sleep Apnea (OSA)1
Not AvailableRecruitingTreatmentPain, Acute1
Not AvailableRecruitingTreatmentPain, Acute / Pain, Chronic1
Not AvailableRecruitingTreatmentPain, Chronic1
Not AvailableRecruitingTreatmentPain / Post Operative Nausea and Vomiting (PONV)1
Not AvailableRecruitingTreatmentPost Laparotomy Pain Treatment1
Not AvailableRecruitingTreatmentSickle Cell Disorders1
Not AvailableSuspendedNot AvailableIschemia-Reperfusion Injury1
Not AvailableSuspendedPreventionInflammatory Reaction1
Not AvailableTerminatedNot AvailableComplications; Cesarean Section / Effects of; Anesthesia, Spinal and Epidural, in Pregnancy / Hemodynamics Instability / Personal Satisfaction1
Not AvailableTerminatedSupportive CareBrain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Pain / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableTerminatedSupportive CareMalignant Neoplasm of Pancreas / Pain1
Not AvailableTerminatedSupportive CarePain / Respiratory Depression1
Not AvailableTerminatedTreatmentLabour Pain1
Not AvailableTerminatedTreatmentPain1
Not AvailableTerminatedTreatmentPostoperative pain1
Not AvailableTerminatedTreatmentPostoperative pain / Shoulder Pain1
Not AvailableUnknown StatusNot AvailableAnalgesic Response1
Not AvailableUnknown StatusTreatmentAbdominal Muscles/Ultrasonography / Adults / Anesthetics, Local/Administration & Dosage / Cesarean Section / Humans / Nerve Block/Methods / Pain Measurement/Methods / Pain, Postoperative/Prevention & Control / Ropivacaine/Administration & Dosage / Ropivacaine/Analogs & Derivatives / Ultrasonography, Interventional1
Not AvailableUnknown StatusTreatmentAbdominal Pain (AP)1
Not AvailableUnknown StatusTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableUnknown StatusTreatmentLiver Dysfunction / Pain1
Not AvailableUnknown StatusTreatmentOsteoarthritis (OA)1
Not AvailableUnknown StatusTreatmentPain2
Not AvailableUnknown StatusTreatmentPain, Acute1
Not AvailableUnknown StatusTreatmentPost Tonsillectomy Pain1
Not AvailableWithdrawnSupportive CareLow Back Pain (LBP)1
Not AvailableWithdrawnTreatmentCaesarean Delivery1
Not AvailableWithdrawnTreatmentUlcers / Wounds and Injuries1

Pharmacoeconomics

Manufacturers
  • King pharmaceuticals inc
  • Actavis elizabeth llc
  • Ekr therapeutics inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Mallinckrodt chemical inc
  • Meridian medical technologies inc
  • Watson laboratories inc
  • Roxane laboratories inc
  • Clonmel healthcare ltd
  • Endo pharmaceuticals inc
  • Kv pharmaceutical co
  • Mallinckrodt inc
  • Purdue pharma lp
  • Xanodyne pharmaceutics inc
  • Actavis
Packagers
Dosage forms
FormRouteStrength
Capsule, coated, extended releaseOral60 mg/1
Capsule, extended releaseOral120 mg/1
Capsule, extended releaseOral45 mg/1
Capsule, extended releaseOral75 mg/1
Capsule, extended releaseOral90 mg/1
InjectionEpidural; Intrathecal; Intravenous.5 mg/mL
InjectionEpidural; Intrathecal; Intravenous1 mg/mL
Capsule, extended releaseOral
Injection, solutionEpidural; Intrathecal10 mg/mL
Injection, solutionEpidural; Intrathecal25 mg/mL
Capsule, extended releaseOral10 mg/1
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral130 mg/1
Capsule, extended releaseOral150 mg/1
Capsule, extended releaseOral20 mg/1
Capsule, extended releaseOral200 mg/1
Capsule, extended releaseOral30 mg/1
Capsule, extended releaseOral40 mg/1
Capsule, extended releaseOral50 mg/1
Capsule, extended releaseOral50 mg
Capsule, extended releaseOral60 mg/1
Capsule, extended releaseOral70 mg/1
Capsule, extended releaseOral80 mg/1
CapsuleOral20 mg/1
CapsuleOral10 mg
CapsuleOral20 mg
CapsuleOral30 mg
CapsuleOral5 mg
Capsule, extended releaseOral10 mg
Capsule, extended releaseOral100 mg
Capsule, extended releaseOral15 mg
Capsule, extended releaseOral200 mg
Capsule, extended releaseOral30 mg
Capsule, extended releaseOral60 mg
TabletOral20 mg
TabletOral40 mg
SyrupOral50 mg
TabletOral60 mg
SolutionIntramuscular; Intravenous; Subcutaneous25 mg
SolutionIntramuscular; Intravenous; Subcutaneous50 mg
SolutionEpidural; Intravenous; Subcutaneous0.5 mg
SolutionEpidural; Intravenous; Subcutaneous1 mg
InjectionIntramuscular10 mg/.7mL
InjectionIntramuscular; Intravenous; Subcutaneous10 mg/mL
InjectionIntramuscular; Intravenous; Subcutaneous15 mg/mL
InjectionIntramuscular; Intravenous; Subcutaneous5 mg/mL
InjectionIntramuscular; Intravenous; Subcutaneous8 mg/mL
InjectionIntravenous1 mg/mL
InjectionIntravenous10 mg/mL
InjectionIntravenous4 mg/mL
InjectionIntravenous8 mg/mL
Injection, solutionEpidural; Intramuscular; Intrathecal; Intravenous2 mg/mL
Injection, solutionEpidural; Intrathecal; Intravenous.5 mg/mL
Injection, solutionEpidural; Intrathecal; Intravenous1 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntramuscular; Intravenous2 mg/mL
Injection, solutionIntramuscular; Intravenous4 mg/mL
Injection, solutionIntramuscular; Intravenous5 mg/mL
Injection, solutionIntramuscular; Intravenous8 mg/mL
Injection, solutionIntrathecal; Intravenous.5 mg/mL
Injection, solutionIntravenous.5 mg/mL
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous15 mg/mL
Injection, solutionIntravenous25 mg/mL
Injection, solutionIntravenous5 mg/mL
Injection, solutionIntravenous; Subcutaneous10 mg/10mL
Injection, solutionIntravenous; Subcutaneous30 mg/30mL
Injection, solution, concentrateIntravenous25 mg/mL
Injection, solution, concentrateIntravenous50 mg/mL
SolutionOral10 mg/5mL
SolutionOral100 mg/5mL
SolutionOral20 mg/5mL
SolutionOral20 mg/mL
Solution, concentrateOral100 mg/5mL
SuppositoryRectal10 mg/1
SuppositoryRectal20 mg/1
SuppositoryRectal30 mg/1
SuppositoryRectal5 mg/1
TabletOral15 mg/1
TabletOral30 mg/1
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral60 mg/1
TabletOral60 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral30 mg/1
TabletOral100 mg/1
TabletOral200 mg/1
Tablet, extended releaseOral15 mg/1
Tablet, extended releaseOral30 mg/1
LiquidIntramuscular; Intravenous; Subcutaneous10 mg
LiquidIntramuscular; Intravenous; Subcutaneous15 mg
SolutionIntravenous; Subcutaneous1 mg
SolutionIntravenous; Subcutaneous2 mg
SolutionIntravenous; Subcutaneous5 mg
SolutionIntramuscular; Intravenous; Subcutaneous1 mg
SolutionIntramuscular; Intravenous; Subcutaneous10 mg
SolutionIntramuscular; Intravenous; Subcutaneous15 mg
SolutionIntramuscular; Intravenous; Subcutaneous2 mg
LiquidIntramuscular; Intravenous; Subcutaneous2 mg
SolutionIntravenous1 mg
SolutionIntravenous5 mg
LiquidIntravenous; Subcutaneous1 mg
LiquidIntramuscular; Intravenous; Subcutaneous25 mg
LiquidIntramuscular; Intravenous; Subcutaneous50 mg
LiquidIntravenous; Subcutaneous2 mg
LiquidIntravenous25 mg
LiquidIntravenous50 mg
LiquidIntravenous1.1 mg
SolutionEpidural0.5 mg
SolutionEpidural1 mg
Tablet, film coated, extended releaseOral15 mg/1
Tablet, film coated, extended releaseOral60 mg/1
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral15 mg
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral30 mg
Tablet, extended releaseOral60 mg
Suppository, extended releaseRectal30 mg
Suppository, extended releaseRectal100 mg
Suppository, extended releaseRectal200 mg
Suppository, extended releaseRectal60 mg
Tablet, extended releaseOral5 mg
Capsule, extended releaseOral150 mg
Capsule, extended releaseOral90 mg
SuppositoryRectal10 mg
Tablet, multilayer, extended releaseOral10 mg
Tablet, multilayer, extended releaseOral20 mg
Tablet, multilayer, extended releaseOral30 mg
Tablet, multilayer, extended releaseOral5 mg
TinctureOral10 mg
SolutionOral1 g/100mL
SolutionOral10 mg/mL
TinctureOral10 mg/mL
LiquidOral2 mg/5mL
SyrupOral20 mg
Solution / dropsOral50 mg
Solution / dropsOral20 mg
SuppositoryRectal20 mg
SuppositoryRectal30 mg
SuppositoryRectal5 mg
SyrupOral10 mg
SyrupOral1 mg
SyrupOral5 mg
TabletOral10 mg
TabletOral5 mg
TabletOral25 mg
TabletOral50 mg
Capsule, extended releaseOral120 mg
Capsule, extended releaseOral20 mg
Capsule, extended releaseOral40 mg
Prices
Unit descriptionCostUnit
Depodur 15 mg/1.5 ml vial618.18USD ml
Roxanol 20 mg/ml Solution 120ml Bottle95.98USD bottle
Morphine Sulfate 20 mg/5ml Solution 500ml Bottle65.05USD bottle
Apokyn 30 mg/3 ml cartridge52.48USD ml
Morphine Sulfate 10 mg/5ml Solution 500ml Bottle38.55USD bottle
Kadian er 200 mg capsule35.43USD capsule
Kadian er 100 mg capsule23.01USD capsule
Roxanol 20 mg/ml Solution 30ml Bottle22.99USD bottle
Morphine Sulfate 10 mg/5ml Solution 100ml Bottle21.99USD bottle
Oramorph sr 60 mg tablet21.76USD tablet
Ms contin 200 mg tablet21.5USD tablet
Kadian er 80 mg capsule18.66USD capsule
Roxanol 20 mg/ml Solution 240ml Bottle17.99USD bottle
Avinza 90 mg capsule17.56USD capsule
Oramorph sr 100 mg tablet17.16USD tablet
Kadian 100 mg 24 Hour Capsule16.93USD capsule
MS Contin 200 mg 12 Hour tablet16.32USD tablet
Kadian 100 mg capsule sr16.25USD capsule
Kadian er 60 mg capsule14.31USD capsule
AVINza 90 mg 24 Hour Capsule13.21USD capsule
Kadian 80 mg capsule sr12.96USD capsule
Avinza 120 mg capsule12.07USD capsule
Kadian er 50 mg capsule11.76USD capsule
Ms contin 100 mg tablet11.75USD tablet
Avinza 60 mg capsule11.58USD capsule
AVINza 120 mg 24 Hour Capsule11.33USD capsule
Avinza 75 mg capsule10.79USD capsule
Morphine sulfate powder10.61USD g
Avinza 45 mg capsule10.22USD capsule
Kadian 60 mg 24 Hour Capsule9.06USD capsule
Morphine Sulfate CR 200 mg 12 Hour tablet8.97USD tablet
MS Contin 100 mg 12 Hour tablet8.89USD tablet
Morphine sulf 30 mg suppository8.44USD suppository
AVINza 60 mg 24 Hour Capsule8.36USD capsule
Ms contin 60 mg tablet7.95USD tablet
Infumorph 10 mg/ml ampul p-f7.8USD ml
Kadian 50 mg 24 Hour Capsule7.71USD capsule
Kadian er 30 mg capsule7.13USD capsule
Oramorph sr 30 mg tablet6.83USD tablet
Morphine sulf 20 mg suppository6.71USD suppository
Kadian er 10 mg capsule6.35USD capsule
Morphine sulf 10 mg suppository6.25USD suppository
Avinza 30 mg capsule6.0USD capsule
MS Contin 60 mg 12 Hour tablet5.71USD tablet
Kadian er 20 mg capsule5.69USD capsule
Ms Contin 200 mg Sustained-Release Tablet5.62USD tablet
Kadian 30 mg 24 Hour Capsule4.8USD capsule
Kadian 20 mg 24 Hour Capsule4.76USD capsule
AVINza 30 mg 24 Hour Capsule4.47USD capsule
Morphine sulf 5 mg suppository4.45USD suppository
Morphine Sulfate CR 100 mg 12 Hour tablet4.33USD tablet
M-Eslon 200 mg Extended-Release Capsule4.3USD capsule
Oramorph sr 15 mg tablet4.12USD tablet
Ms contin cr 30 mg tablet4.09USD tablet
Kadian 10 mg capsule sr4.05USD capsule
Morphine Hp 50 50 mg/ml4.01USD ml
Kadian 10 mg 24 Hour Capsule4.0USD capsule
Ms contin 15 mg tablet3.58USD tablet
MS Contin 30 mg 12 Hour tablet3.26USD tablet
Novo-Morphine Sr 200 mg Sustained-Release Tablet3.09USD tablet
Pms-Morphine Sulfate Sr 200 mg Sustained-Release Tablet3.09USD tablet
Ms Contin 100 mg Sustained-Release Tablet3.02USD tablet
Morphine Sulfate CR 60 mg 12 Hour tablet3.0USD tablet
Morphine Hp 25 25 mg/ml2.9USD ml
Statex 30 mg Suppository2.55USD suppository
Kadian 100 mg Sustained-Release Capsule2.35USD capsule
Statex 20 mg Suppository2.32USD suppository
Morphine Lp Epidural 1 mg/ml2.24USD ml
M-Eslon 100 mg Extended-Release Capsule2.15USD capsule
MS Contin 15 mg 12 Hour tablet2.13USD tablet
Ms Contin 60 mg Sustained-Release Tablet1.98USD tablet
Statex 10 mg Suppository1.95USD suppository
Morph sulf 5 mg/0.25 ml vial1.83USD vial
Statex 5 mg Suppository1.75USD suppository
Novo-Morphine Sr 100 mg Sustained-Release Tablet1.66USD tablet
Pms-Morphine Sulfate Sr 100 mg Sustained-Release Tablet1.66USD tablet
Morphine Sulfate CR 30 mg 12 Hour tablet1.63USD tablet
Morphine 8 mg/ml ampule1.56USD ml
Kadian 50 mg Sustained-Release Capsule1.35USD capsule
Duramorph 0.5 mg/ml ampul1.31USD ml
Astramorph-pf 1 mg/ml ampul1.15USD ml
Ms Contin 30 mg Sustained-Release Tablet1.13USD tablet
Morphine Lp Epidural 0.5 mg/ml1.12USD ml
Morphine Sulfate 15 mg/ml1.03USD ml
Morphine Sulfate 10 mg/ml1.02USD ml
Novo-Morphine Sr 60 mg Sustained-Release Tablet1.01USD tablet
Pms-Morphine Sulfate Sr 60 mg Sustained-Release Tablet1.01USD tablet
Ratio-Morphine Sulfate Sr 60 mg Sustained-Release Tablet1.01USD tablet
M-Eslon 60 mg Extended-Release Capsule1.0USD capsule
Statex 50 mg/ml Drops0.99USD ml
Morphine Sulfate CR 15 mg 12 Hour tablet0.93USD tablet
Duramorph 1 mg/ml ampul0.91USD ml
M.O.S.-Sr 60 mg Sustained-Release Tablet0.89USD tablet
Morphine 50 mg/25 ml-d5w syr0.86USD ml
Morphine-ns 10 mg/ml syringe0.86USD ml
Morphine-ns 5 mg/ml syringe0.8USD ml
Ms Contin 15 mg Sustained-Release Tablet0.75USD tablet
Morphine 5 mg/ml vial0.74USD ml
Kadian 20 mg Sustained-Release Capsule0.73USD capsule
Astramorph-pf 0.5 mg/ml amp0.72USD ml
Morphine Sulfate 15 mg tablet0.65USD tablet
Morphine Sulfate 30 mg tablet0.65USD tablet
Morphine 1 mg/ml vial p-f0.6USD ml
Morphine-ns 1 mg/ml syringe0.58USD ml
Novo-Morphine Sr 30 mg Sustained-Release Tablet0.57USD tablet
Pms-Morphine Sulfate Sr 30 mg Sustained-Release Tablet0.57USD tablet
Ratio-Morphine Sulfate Sr 30 mg Sustained-Release Tablet0.57USD tablet
M-Eslon 30 mg Extended-Release Capsule0.56USD capsule
Morphine 0.5 mg/ml vial0.55USD ml
Morphine sulfate 50 mg/ml vial0.55USD ml
Morphine sulfate ir 30 mg tablet0.55USD tablet
Ratio-Morphine 20 mg/ml Syrup0.55USD syrup
Statex 20 mg/ml Drops0.52USD ml
M.O.S.-Sr 30 mg Sustained-Release Tablet0.51USD tablet
Morphine 1 mg/ml syringe0.48USD ml
Morphine 10 mg/ml vial0.48USD ml
Ms.Ir 30 mg Tablet0.48USD tablet
Morphine sulfate 25 mg/ml vial0.43USD ml
Morphine sulf 1 mg/ml vial0.4USD ml
M.O.S. Sulfate 50 mg Tablet0.39USD tablet
Statex 50 mg Tablet0.39USD tablet
Kadian 10 mg Sustained-Release Capsule0.38USD capsule
M-Eslon 15 mg Extended-Release Capsule0.38USD capsule
Ms.Ir 20 mg Tablet0.38USD tablet
Novo-Morphine Sr 15 mg Sustained-Release Tablet0.37USD tablet
Pms-Morphine Sulfate Sr 15 mg Sustained-Release Tablet0.37USD tablet
Ratio-Morphine Sulfate Sr 15 mg Sustained-Release Tablet0.37USD tablet
M-Eslon 10 mg Extended-Release Capsule0.33USD capsule
Morphine sulfate ir 15 mg tablet0.32USD tablet
Morphine 15 mg/ml vial0.3USD ml
Morphine-ns 25 mg/25 ml syr0.26USD ml
M.O.S. Sulfate 25 mg Tablet0.25USD tablet
Statex 25 mg Tablet0.25USD tablet
Ms.Ir 10 mg Tablet0.21USD tablet
Ratio-Morphine 10 mg/ml Syrup0.19USD syrup
M.O.S. Sulfate 10 mg Tablet0.19USD tablet
Statex 10 mg Tablet0.19USD tablet
Morphine-ns 5 mg/ml0.16USD ml
Morphine-ns 55 mg/55 ml syr0.14USD ml
Ms.Ir 5 mg Tablet0.14USD tablet
M.O.S. Sulfate 5 mg Tablet0.12USD tablet
Statex 5 mg Tablet0.12USD tablet
Morphine 1 mg/ml-d5w 100 ml0.1USD ml
Morphine-ns 150 mg/150 ml0.1USD ml
Statex 5 mg/ml Syrup0.08USD ml
Morphine 1 mg/ml-d5w 250 ml0.06USD ml
Ratio-Morphine 5 mg/ml Syrup0.05USD syrup
Ratio-Morphine 1 mg/ml Syrup0.02USD syrup
Statex 1 mg/ml Syrup0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5378474No1993-03-232010-03-23Us
CA2065210No2000-08-292012-04-06Canada
CA2128591No1999-03-232014-07-21Canada
US6066339No1997-11-252017-11-25Us
US5931809No1995-07-142015-07-14Us
US5962016No1997-01-312017-01-31Us
US6193998No1996-09-012016-09-01Us
US5997899No1996-09-012016-09-01Us
US6241999No1996-09-012016-09-01Us
US5807572No1995-09-152015-09-15Us
US5891467No1997-01-312017-01-31Us
US6171613No1996-10-012016-10-01Us
US8685443No2005-07-032025-07-03Us
US8158156No2007-06-192027-06-19Us
US7682633No2007-06-192027-06-19Us
US8623418No2009-11-072029-11-07Us
US8685444No2005-07-032025-07-03Us
US8846104No2007-06-192027-06-19Us
US7815934No2007-12-122027-12-12Us
US7682634No2007-06-192027-06-19Us
US8877247No2007-06-192027-06-19Us
US9192608No2014-03-122034-03-12Us
US9072781No2014-03-122034-03-12Us
US9248229No2014-03-122034-03-12Us
US7955619No2008-08-122028-08-12Us
US9044402No2013-07-012033-07-01Us
US9549899No2013-07-012033-07-01Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)255 °CPhysProp
water solubility149 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.89AVDEEF,A ET AL. (1996)
logS-3.28ADME Research, USCD
pKa8.21 (at 25 °C)LIDE,DR (1995)
Predicted Properties
PropertyValueSource
Water Solubility10.2 mg/mLALOGPS
logP0.99ALOGPS
logP0.9ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)10.26ChemAxon
pKa (Strongest Basic)9.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area52.93 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity80.12 m3·mol-1ChemAxon
Polarizability29.95 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9971
Blood Brain Barrier+0.9882
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.8787
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.956
Renal organic cation transporterInhibitor0.6221
CYP450 2C9 substrateNon-substrate0.7451
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7375
CYP450 1A2 substrateNon-inhibitor0.5191
CYP450 2C9 inhibitorNon-inhibitor0.9046
CYP450 2D6 inhibitorNon-inhibitor0.647
CYP450 2C19 inhibitorNon-inhibitor0.8155
CYP450 3A4 inhibitorNon-inhibitor0.9176
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7503
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9634
BiodegradationNot ready biodegradable0.9944
Rat acute toxicity2.8989 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Non-inhibitor0.874
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.42 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00li-8970000000-28acaf307ce4bc5aabf1
GC-MS Spectrum - CI-BGC-MSsplash10-014i-0090000000-b9cf42b077ae0fa5b50d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0090000000-98125212ed8e73f219e1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0090000000-e9f7be236d827a716c1b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0290000000-5066e10cd96a2c376676
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0kui-0930000000-793deeb91de6d2459cbe
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-100r-0900000000-f775c77035946f746daa
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ufr-0390000000-660ff44516f98e346016
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-22857c8ef81e65ad6bd3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-c5194c99a9e7f30ea0c8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-1980ff8ab9e654f16fe1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0690000000-efa51d970eaf96d3b982
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pc9-0920000000-64a693f2f51c03129c94
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-100r-0900000000-49174c3db4b1c1847080
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-3cc8784093ef460d3030
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-4bc885836f18b77696f3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-4a16648c3e86669f2446
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0690000000-f41b2f804790e9ad8f1d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pc9-0920000000-69393fc6563baf39d91f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-100r-0900000000-467f39309be5edfa4c01
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ufr-0390000000-bd9670761ff2a7dafc55

Taxonomy

Description
This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Morphinans
Sub Class
Not Available
Direct Parent
Morphinans
Alternative Parents
Phenanthrenes and derivatives / Tetralins / Coumarans / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Trialkylamines / Secondary alcohols / Oxacyclic compounds
show 3 more
Substituents
Morphinan / Phenanthrene / Tetralin / Coumaran / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / Benzenoid / Secondary alcohol
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
morphinane alkaloid, organic heteropentacyclic compound (CHEBI:17303) / Alkaloids, Isoquinoline alkaloids (C01516)

Targets

Details
1. Mu-type opioid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10. [PubMed:16530171]
  2. Choi HS, Kim CS, Hwang CK, Song KY, Wang W, Qiu Y, Law PY, Wei LN, Loh HH: The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun. 2006 May 19;343(4):1132-40. Epub 2006 Mar 23. [PubMed:16580639]
  3. Castro RR, Cunha FQ, Silva FS Jr, Rocha FA: A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide. Osteoarthritis Cartilage. 2006 Aug;14(8):769-76. Epub 2006 Mar 31. [PubMed:16580848]
  4. Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, Henderson G: Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol. 2006 Aug;70(2):676-85. Epub 2006 May 8. [PubMed:16682505]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. doi:10.1021/cn9000236 [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Leventhal L, Silva RM, Rossi GC, Pasternak GW, Bodnar RJ: Morphine-6beta-glucuronide-induced hyperphagia: characterization of opioid action by selective antagonists and antisense mapping in rats. J Pharmacol Exp Ther. 1998 Nov;287(2):538-44. [PubMed:9808678]
  4. Kozak CA, Filie J, Adamson MC, Chen Y, Yu L: Murine chromosomal location of the mu and kappa opioid receptor genes. Genomics. 1994 Jun;21(3):659-61. [PubMed:7959748]
  5. Teodorov E, Modena CC, Sukikara MH, Felicio LF: Preliminary study of the effects of morphine treatment on opioid receptor gene expression in brain structures of the female rat. Neuroscience. 2006 Sep 1;141(3):1225-31. Epub 2006 Jun 6. [PubMed:16753266]
  6. doi:10.1021/cn9000236 [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10. [PubMed:16530171]
  2. Dortch-Carnes J, Russell KR: Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide. Pharmacology. 2006;77(1):17-24. Epub 2006 Mar 13. [PubMed:16534251]
  3. Koch T, Wu DF, Yang LQ, Brandenburg LO, Hollt V: Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors. J Neurochem. 2006 Apr;97(2):365-72. Epub 2006 Mar 15. [PubMed:16539674]
  4. Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C: Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain. 2006 Aug;123(3):294-305. Epub 2006 May 2. [PubMed:16650582]
  5. Asensio VJ, Miralles A, Garcia-Sevilla JA: Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal. Eur J Pharmacol. 2006 Jun 6;539(1-2):49-56. Epub 2006 Apr 6. [PubMed:16678156]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Kieffer BL, Gaveriaux-Ruff C: Exploring the opioid system by gene knockout. Prog Neurobiol. 2002 Apr;66(5):285-306. [PubMed:12015197]
  8. doi:10.1021/cn9000236 [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Lipopolysaccharide receptor activity
Specific Function
Binds bacterial lipopolysaccharide (LPS) (PubMed:17803912, PubMed:17569869). Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response ...
Gene Name
LY96
Uniprot ID
Q9Y6Y9
Uniprot Name
Lymphocyte antigen 96
Molecular Weight
18545.345 Da
References
  1. Hutchinson MR, Lewis SS, Coats BD, Rezvani N, Zhang Y, Wieseler JL, Somogyi AA, Yin H, Maier SF, Rice KC, Watkins LR: Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience. 2010 May 19;167(3):880-93. doi: 10.1016/j.neuroscience.2010.02.011. Epub 2010 Feb 21. [PubMed:20178837]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
3. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Coffman BL, Rios GR, King CD, Tephly TR: Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4. [PubMed:9010622]
  2. Takeda S, Ishii Y, Iwanaga M, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H: Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol Pharmacol. 2005 Mar;67(3):665-72. Epub 2004 Dec 20. [PubMed:15611481]
  3. Yamada H, Ishii K, Ishii Y, Ieiri I, Nishio S, Morioka T, Oguri K: Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci. 2003 Dec;28(5):395-401. [PubMed:14746343]
  4. Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [PubMed:20071451]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Ohno S, Kawana K, Nakajin S: Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94. doi: 10.1124/dmd.107.019281. Epub 2008 Jan 10. [PubMed:18187562]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A8
Uniprot ID
Q9HAW9
Uniprot Name
UDP-glucuronosyltransferase 1-8
Molecular Weight
59741.035 Da
References
  1. Ohno S, Kawana K, Nakajin S: Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94. doi: 10.1124/dmd.107.019281. Epub 2008 Jan 10. [PubMed:18187562]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xeno...
Gene Name
UGT2B15
Uniprot ID
P54855
Uniprot Name
UDP-glucuronosyltransferase 2B15
Molecular Weight
61035.815 Da
References
  1. Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [PubMed:20071451]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
Gene Name
UGT2B4
Uniprot ID
P06133
Uniprot Name
UDP-glucuronosyltransferase 2B4
Molecular Weight
60512.035 Da
References
  1. Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [PubMed:20071451]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR: Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12. [PubMed:9616184]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  2. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18